Enzymatica AB: The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million
Press release October 18, 2018 The Board of Directors of Enzymatica AB decides on rights issue of SEK 98.7 million The Board of Directors of Enzymatica AB (publ) has decided to carry out a rights issue of a maximum of SEK 98,678,187.20 with preferential rights for existing shareholders. The purpose of the rights issue is to finance continued marketing campaigns and clinical studies on the efficacy of ColdZyme besides repaying a bridge loan. The rights issue is subject to approval by an Extraordinary General Meeting to be held on November 5, 2018. Under the terms of the rights issue,